Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Rheumatoid Arthritis Age: Adult |
Dose: Oral – 1 mg/kg/day Frequency: initially in single daily dose or divided every 12 hours Note: May be increased by 0.5 mg/kg/day after 6-8 weeks, then by 0.5 mg/kg/day every 4 weeks; not to exceed 2.5 mg/kg/day |
|
Indication: Rheumatoid Arthritis Age: Adult |
Dose: Oral – Reduce daily dose by 0.5 mg/kg Frequency: every 4 weeks Note: Maintenance dose until the lowest effective dosage is reached |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Juvenile Idiopathic Arthritis Age: Juvenile |
Dose: Oral – 1 mg/kg/day Frequency: initially in single daily dose or divided every 12 hours Note: by mouth (oral); may be increased by 0.5 mg/kg/day after 6-8 weeks, then by 0.5 mg/kg/day every 4 weeks; not to exceed 2.5 mg/kg/day |
|
Indication: Juvenile Idiopathic Arthritis Age: Juvenile Condition: Maintenance |
Dose: Oral – Reduce daily dose by 0.5 mg/kg Duration: every 4 weeks Note: by mouth (oral); until the lowest effective dosage is reached |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: - Note: Dose adjustments Reduce dose. |
Administration
- Can be taken with or without food
- Take with food if stomach upset occurs
Side Effect
- Leukopenia (28-50%)
- Infection (20%)
- Lymphoma
- Fever
- chills
- bone marrow depression
- thrombocytopenia or anaemia
- anorexia
- nausea
- diarrhoea
- arthralgias
- secondary infections
- hepatotoxicity
- rash
- alopoecia
- Myelosuppression
- mutagenicity and carcinogenicity
- veno-occlussive liver disease
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Aminosalicylates, drugs that affect myelopoesis (e.g. co-trimoxazole or trimethoprim)
|
Increased risk of haematotoxicity
|
|
Intra-uterine devices, live vaccines
|
Increased risk of infections
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Hypersensitivity
|
Risk of severe allergic reaction
|
|
Previous Treatment With Alkylating Agents
|
Risk of excessive bone marrow suppression
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Azathioprine should be stored at 15 to 25° C in a dry place and protected from light.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.